IP Library › Granted Patent US 11,484,550
Granted Patent B2
US 11,484,550 · App. 17/113,904 · Granted Nov 1, 2022

Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof

Inventors: Peter Novak (Sunny Isles Beach, FL); Maxim Temnikov (Miami, FL); Oleksandr Balakin (Dnepropetrovsk, UA)
Assignee: VECTOR VITALE IP LLC
A61K33/30A23L33/10A23L33/16A61K31/704A61K33/00A61K33/06A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,484,550
App. No.
17/113,904
Granted
Nov 1, 2022
Kind
B2
Abstract

A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals.

Claims (10)

1. A therapeutic composition comprising a therapeutically effective amount of more than one of 39 K-enriched potassium, 24 Mg-enriched magnesium, 64 Zn-enriched zinc, 85 Rb-enriched rubidium, and 28 Si-enriched silicon, present as an element or in the form of a pharmaceutically acceptable salt, compound or complex thereof, and at least one excipient; wherein the 39 K-enriched potassium is at least about 98% 39 K, the 24 Mg-enriched magnesium is at least about 95% 24 Mg, the 64 Zn-enriched zinc is at least about 90% 64 Zn, the 85 Rb-enriched rubidium is at least about 90% 85 Rb, and the 28 Si-enriched silicon is at least about 95% 28 Si.

2. The composition of claim 1 , wherein the composition contains 39 K-enriched potassium and wherein the composition contains between 1 g and 14.5 g of 39 K.

3. The composition of claim 1 , wherein the composition contains 24 Mg-enriched magnesium.

4. The composition of claim 3 , wherein the composition contains between 10 mg and 13 g of 24 Mg.

5. The composition of claim 1 , wherein the composition contains 64 Zn-enriched zinc.

6. The composition of claim 5 , wherein the composition contains between 0.6 mg and 330 mg of 64 Zn.

7. The composition of claim 1 , wherein the composition contains 85 Rb-enriched rubidium.

8. The composition of claim 7 , wherein the composition contains between 0.3 mg and 60 mg of 85 Rb.

9. The composition of claim 1 , wherein the composition contains 28 Si-enriched silicon.

10. The composition of claim 9 , wherein the composition contains between 3.3 mg and 300 mg of 28 Si.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2021
From: BALAKIN, OLEKSANDR
To: NOVAK, PETER Y.; TEMNIKOV, MAXIM V.
Reel/Frame 055213/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2021
From: NOVAK, PETER Y.; TEMNIKOV, MAXIM V.
To: VECTOR VITALE IP LLC
Reel/Frame 055214/0066 →
Continuity (5)
Continuation 16236343 · Dec 29, 2018
Continuation 15613109 · Jun 2, 2017
Continuation In Part 14833114 · Aug 23, 2015
Provisional Application 62123900 · Dec 1, 2014
Related Publication 20210093663A1 · Apr 1, 2021
Cited By (2)
US 12,527,820 US 12,734,240